2025. Evaluation of Paclitaxel as a Non-Cross-Resistant Agent in Cisplatin-Resistant Small Cell Lung Cancer (SCLC). International Cancer Research Journal. 1, 1 (Sep. 2025), 2. DOI:https://doi.org/10.70844/icrj.2025.1.2.